286 related articles for article (PubMed ID: 28711736)
1. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
Kometer M; Pokorny T; Seifritz E; Volleinweider FX
Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
[TBL] [Abstract][Full Text] [Related]
4. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
Carhart-Harris RL; Erritzoe D; Williams T; Stone JM; Reed LJ; Colasanti A; Tyacke RJ; Leech R; Malizia AL; Murphy K; Hobden P; Evans J; Feilding A; Wise RG; Nutt DJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):2138-43. PubMed ID: 22308440
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.
Vollenweider FX; Leenders KL; Scharfetter C; Maguire P; Stadelmann O; Angst J
Neuropsychopharmacology; 1997 May; 16(5):357-72. PubMed ID: 9109107
[TBL] [Abstract][Full Text] [Related]
7. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
8. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
Carter OL; Pettigrew JD; Hasler F; Wallis GM; Liu GB; Hell D; Vollenweider FX
Neuropsychopharmacology; 2005 Jun; 30(6):1154-62. PubMed ID: 15688092
[TBL] [Abstract][Full Text] [Related]
9. Effects of varied doses of psilocybin on time interval reproduction in human subjects.
Wackermann J; Wittmann M; Hasler F; Vollenweider FX
Neurosci Lett; 2008 Apr; 435(1):51-5. PubMed ID: 18325673
[TBL] [Abstract][Full Text] [Related]
10. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
[TBL] [Abstract][Full Text] [Related]
11. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
12. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
Gouzoulis-Mayfrank E; Schreckenberger M; Sabri O; Arning C; Thelen B; Spitzer M; Kovar KA; Hermle L; Büll U; Sass H
Neuropsychopharmacology; 1999 Jun; 20(6):565-81. PubMed ID: 10327426
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
14. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.
Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ
J Psychopharmacol; 2011 Nov; 25(11):1562-7. PubMed ID: 20395317
[TBL] [Abstract][Full Text] [Related]
15. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Carbonaro TM; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
[TBL] [Abstract][Full Text] [Related]
16. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
17. Enhanced repertoire of brain dynamical states during the psychedelic experience.
Tagliazucchi E; Carhart-Harris R; Leech R; Nutt D; Chialvo DR
Hum Brain Mapp; 2014 Nov; 35(11):5442-56. PubMed ID: 24989126
[TBL] [Abstract][Full Text] [Related]
18. Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.
Lewis CR; Preller KH; Braden BB; Riecken C; Vollenweider FX
Biomedicines; 2020 Feb; 8(2):. PubMed ID: 32085521
[TBL] [Abstract][Full Text] [Related]
19. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
[TBL] [Abstract][Full Text] [Related]
20. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD
Sci Rep; 2017 Apr; 7():46421. PubMed ID: 28422113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
